Final Results from Arq 197-209: A Global Randomized Placebo-controlled Phase 2 Clinical Trial of Erlotinib Plus ARQ 197 Versus Erlotinib Plus Placebo in Previously Treated EGER-inhibitor Naive Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Von Pawel, J. [1 ]
Akerley, W. [2 ]
Brugger, W. [3 ]
Ferrari, D. [4 ]
Garmey, E. [4 ]
Gerber, D. [5 ]
Orlov, S. [6 ]
Ramlau, R. [7 ]
Sequist, L. [8 ]
Schiller, J. [5 ]
机构：
[1] Asklepios Klinikum Gauting, Munich, Germany
[2] Univ Utah, Huntsman Canc Inst, Huntsman Canc Inst Canc Care Program, Salt Lake City, UT USA
[3] Schwarzwald Baar Clin, Schwenningen, Germany
[4] Ar Qule Inc, Woburn, MA USA
[5] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[6] St Petersburg Pavlov State Med Univ, St Petersburg, Russia
[7] Wielkopolskie Centrum Chorob Pluc & Gruzlicy, Poznan, Poland
[8] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S501 / S501
页数：1
相关论文
共 50 条
  • [41] Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer
    Heymach, John V.
    Johnson, Bruce E.
    Prager, Diane
    Csada, Edit
    Roubec, Jaromir
    Pesek, Milos
    Spasova, Irena
    Belani, Chandra P.
    Bodrogi, Istvan
    Gadgeel, Shirish
    Kennedy, Sarah J.
    Hou, Jeannie
    Herbst, Roy S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) : 4270 - 4277
  • [42] Vandetanib versus erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial
    Goss, G. D.
    Thongprasert, S.
    Greco, F. A.
    Thomas, M.
    Tsai, C. M.
    Sunpaweravong, P.
    Ferry, D.
    Gogov, S.
    Rowbottom, J. A.
    Natale, R. B.
    EJC SUPPLEMENTS, 2009, 7 (02): : 506 - 506
  • [43] Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E plus fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).
    Garon, Edward B.
    Siegfried, Jill M.
    Dubinett, Steven M.
    Elashoff, Robert M.
    Park, David J.
    Parikh, Rupesh J.
    Patel, Ravi
    Hu, Eddie H.
    Reckamp, Karen L.
    Adams, Brad
    Martinez, Diego
    Wang, He-Jing
    Kabbinavar, Fairooz
    Dacic, Sanja
    Brennan, Meghan
    Laux, Isett
    Marquez-Garban, Diana C.
    Stabile, Laura P.
    Slamon, Dennis J.
    Pietras, Richard J.
    CANCER RESEARCH, 2013, 73 (08)
  • [44] RANDOMIZED PHASE II STUDY OF SUNITINIB (SU) PLUS ERLOTINIB (E) VS. PLACEBO (P) PLUS E FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
    Groen, H. J. M.
    Socinski, M.
    Grossi, F.
    Juhasz, E.
    Gridelli, C.
    Baas, P.
    Usari, T.
    Tye, L.
    Chao, R.
    Blumenschein, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 139 - 139
  • [45] National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21. A placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC)
    Ciuleanu, T. E.
    Shepherd, F.
    Pereira, J.
    Tan, E. H.
    Hirsch, V.
    Thongprasert, S.
    Bezjak, A.
    Ding, K.
    Ptaszynski, M.
    Seymour, L.
    ANNALS OF ONCOLOGY, 2004, 15 : 14 - 14
  • [46] Randomized, double-blind, placebo-controlled, phase III multicentre study of paclitaxel plus carboplatin (TC) versus TC plus endostar in patients with advanced non-small cell lung cancer (NSCLC)
    Han Baohui
    Xiu Qingyu
    Wang Huiming
    Luo Yi
    Bai Chunxue
    Guo Shuliang
    Liu Wenchao
    Zhuang Zhixiang
    Zhang Yang
    Zhou Jianying
    Jing Xianqiao
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S353 - S354
  • [47] Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: preliminary results
    Ross, HJ
    Blumenschein, GR
    Dowlati, A
    Aisner, J
    Rigas, JR
    Stanislaus, M
    Leopold, LH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 645S - 645S
  • [48] Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy
    Felip, E
    Rojo, F
    Heller, A
    Foernzler, D
    Majo, J
    Klughammer, B
    Ramos, J
    Maacke, H
    Brennscheidt, U
    Baselga, J
    LUNG CANCER, 2005, 49 : S369 - S369
  • [49] Randomized phase II trial of erlotinib (E) plus high-dose celecoxib (HD-C) or placebo (P) in advanced non-small cell lung cancer
    Reckamp, Karen L.
    Koczywas, Marianna
    Cristea, Mihaela C.
    Dowell, Jonathan
    Gardner, Brian
    Milne, Ginger L.
    Figlin, Robert A.
    Elashoff, Robert M.
    Dubinett, Steven M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung (vol 35, pg 412, 2017)
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 833 - 833
12345